Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31476387 | 1.00 | IDO1 (0.47) | IDO1TDO2ALDH1A1MAPK1CYP3A4 | |
| SCHEMBL4678 | 0.93 | IDO1 (0.52) | IDO1TDO2ALDH1A1SLC18A3SIGMAR1 | |
| SCHEMBL3346119 | 0.88 | ACP3 (0.42) | IDO1TDO2CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL10673316 | 0.86 | CYP3A4 (0.43) | IDO1TDO2MAPK1CYP3A4CYP2D6 | |
| SCHEMBL8806183 | 0.86 | ALDH1A1 (0.47) | IDO1TDO2ALDH1A1MAPK1CYP3A4 | |
| SCHEMBL5773097 | 0.85 | CYP3A4 (0.47) | IDO1TDO2ALDH1A1MAPK1CYP3A4 | |
| SCHEMBL5911692 | 0.85 | CYP3A4 (0.47) | IDO1TDO2ALDH1A1MAPK1CYP3A4 | |
| SCHEMBL5872085 | 0.85 | IDO1 (0.47) | IDO1TDO2ALDH1A1MAPK1CYP3A4 | |
| SCHEMBL20139452 | 0.84 | ALDH1A1 (0.40) | IDO1TDO2ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL10439663 | 0.84 | MAOB (0.42) | IDO1TDO2CYP3A4CYP2D6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5576417-A | Method for synthesizing aromatic polymers | DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1996-11-19 | — | — | US | claimed |
| US-20250115628-A1 | FLUORINATED FLUOROPHORES | HOWARD HUGHES MEDICAL INSTITUTE | 2025-04-10 | — | — | US | disclosed |
| US-20230285378-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2023-09-14 | — | — | US | disclosed |
| CN-113402462-A | Condensed ring compound, preparation method and application thereof, co-host material, light-emitting composition, light-emitting device, lighting device and display device | 中国石油化工股份有限公司 | 2021-09-17 | — | — | CN | disclosed |
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-20190015402-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-10039754-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-10028937-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2678334-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2627651-A1 | ANTI-VIRAL COMPOUNDS | Abbvie Inc. (US) | 2013-08-21 | — | — | EP | disclosed |
| US-20120220562-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2012116257-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2012-08-30 | — | — | WO | disclosed |
| US-8173696-B2 | Inhibitors of cysteine proteases and methods of use thereof | BAYLOR UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2012051361-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-04-19 | — | — | WO | disclosed |
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | BAYLOR UNIVERSITY (US) | 2009-03-19 | — | — | US | disclosed |
| US-20060202197-A1 | Platinum complex and light-emitting device | TAKASAGO INTERNATIONAL CORPORATION | 2006-09-14 | — | — | US | disclosed |
| US-5576417-A | Method for synthesizing aromatic polymers | DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1996-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10028937-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | IDO1 2992/4885TDO2 4629/4885ALDH1A1 2858/4885 |
| US-20230285378-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | IDO1 2992/4885TDO2 4629/4885ALDH1A1 2858/4885 |
| US-20120220562-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | IDO1 2992/4885TDO2 4629/4885ALDH1A1 2858/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | IDO1 2992/4885TDO2 4629/4885ALDH1A1 2858/4885 |
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSB, CTSS, CTSZ | IDO1 1605/4885TDO2 1850/4885ALDH1A1 1623/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | IDO1 2992/4885TDO2 4629/4885ALDH1A1 2858/4885 |
| US-20250115628-A1 | FLUORINATED FLUOROPHORES | PFAS, FLI1, ARFGEF1 | IDO1 3749/4885TDO2 1525/4885ALDH1A1 1109/4885 |
| US-20060202197-A1 | Platinum complex and light-emitting device | RAD1, RAD51, UACA | IDO1 1339/4885TDO2 1064/4885ALDH1A1 1848/4885 |
| US-20190015402-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | IDO1 2992/4885TDO2 4629/4885ALDH1A1 2858/4885 |
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | IDO1 2992/4885TDO2 4629/4885ALDH1A1 2858/4885 |
| US-10039754-B2 | Anti-viral compounds | HAVCR2, EIF2AK2, MAVS | IDO1 2992/4885TDO2 4629/4885ALDH1A1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.